Observational studyThe Lancet. Infectious diseases2021
Measuring health-care delays among privately insured patients with tuberculosis in the USA: an observational cohort study.
Observational study in The Lancet. Infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 24 citations in OpenAlex.
- Tuberculosis Disease Severity Assessment Using Clinical Variables and Radiology Enabled by Artificial Intelligence.The Journal of infectious diseases · 2026Article
- "Fragmented care pathway in a layered TB care system": a grounded theory approach to understand care pathways and delays in TB care in Odisha.BMC health services research · 2026Article
- Healthcare system strain and healthcare seeking behavior: the lingering impact of the COVID-19 pandemic on TB delayed diagnosis in Snohomish County, Washington.Journal of clinical tuberculosis and other mycobacterial diseases · 2026Article
- Stakeholder engagement to identify barriers to implementation and inform the development of point-of-care diagnostics for TB.IJTLD open · 2026Article
- Trends in Active Tuberculosis Cases Diagnosed in New York City During the COVID-19 Pandemic.Public health reports (Washington, D.C. : 1974) · 2026Article
- Contribution of Posttuberculosis Sequelae to Life-Years Lost from Tuberculosis Disease in the United States, 2015-2019.American journal of respiratory and critical care medicine · 2025Article
- Patient pathway analysis of rifampicin-resistant TB diagnostic and treatment delays.IJTLD open · 2025Article
- Awareness of management of pulmonary multidrug-resistant tuberculosis (MDR-TB) among private practitioners in suburban areas of Pune city, India: Input for developing an educational tool.PLOS global public health · 2025Article
- Analysis of diagnosis delay among migrant pulmonary tuberculosis patients in Guangzhou from 2014 to 2022.Frontiers in public health · 2025Article
- Drug-resistant tuberculosis: a persistent global health concern.Nature reviews. Microbiology · 2024Review
- Analyzing spatial delays of tuberculosis from surveillance and awareness surveys in Eastern China.Scientific reports · 2024Article
- Timely Pulmonary Tuberculosis Diagnosis Based on the Epidemiological Disease Spectrum: Population-Based Prospective Cohort Study in the Republic of Korea.JMIR public health and surveillance · 2024Article
- Racial and ethnic disparities in diagnosis and treatment outcomes among US-born people diagnosed with tuberculosis, 2003-19: an analysis of national surveillance data.The Lancet. Public health · 2024Article
- Time-trend analysis of tuberculosis diagnosis in Shenzhen, China between 2011 and 2020.Frontiers in public health · 2023Article
- Tuberculosis in Dialysis Patients in the Central Region of Morocco: What Is the Health-Care Delay?Cureus · 2022Article
- Association between diagnostic delay and prognosis of pulmonary tuberculosis in Shandong, China: a retrospective study.BMC pulmonary medicine · 2022Article
- Time delays and risk factors in the management of patients with active pulmonary tuberculosis: nationwide cohort study.Scientific reports · 2022Article
- Multidrug-resistant tuberculosis control in Rwanda overcomes a successful clone that causes most disease over a quarter century.Journal of clinical tuberculosis and other mycobacterial diseases · 2022Review
- Identifying Risk Factors for Pulmonary Tuberculosis Diagnosis Delays in Mali a West-African Endemic Country.Journal of tuberculosis research · 2022Article
- Tuberculosis Pathways to Care and Transmission of Multidrug Resistance in India.American journal of respiratory and critical care medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundA high index of suspicion is needed to initiate appropriate testing for tuberculosis due to its protean symptoms, yet health-care providers in low-incidence settings are becoming less familiar with the disease as rates decline. We aimed to estimate delays in tuberculosis diagnosis and treatment at the US national level between 2008 and 2016.
methodsIn this retrospective observational cohort study, we repurposed private insurance claims data provided by Aetna (Connecticut, USA), to measure health-care delays in tuberculosis diagnosis in the USA in 2008-16. Active tuberculosis was determined by diagnosis codes and the filling of anti-tuberculosis treatment prescriptions. Health-care delays were defined as the duration between the first health-care visit for a tuberculosis symptom and the initiation of anti-tuberculosis treatment. We assessed if delays varied over time, and by patient and system variables, using multivariable regression. We estimated household tuberculosis transmission and respiratory complications after treatment initiation.
findingsWe confirmed 738 active tuberculosis cases (incidence 1·45 per 100 000 person-years) with a median health-care delay of 24 days (IQR 10-45). Multivariable regression analysis showed that longer delays were associated with older age (8·4% per 10 year increase [95% CI 4·0 to 13·1]; p<0·0086) and non-HIV immunosuppression (19·2% [15·1 to 60·0]; p=0·0432). Presenting with three or more symptoms was associated with a shorter delay (-22·5% [-39·1 to -2·0]; p=0·0415), relative to presenting with one symptom, as did use of chest imaging (-24·9% [-37·9 to -8·9]; p<0·0098), tuberculosis nucleic acid amplification tests (-19·2% [-32·7 to -3·1]; p=0·0241), and care by a tuberculosis specialist provider (-17·2% [-33·1 to -22·3]; p<0·0087). Longer delays were associated with an increased rate of respiratory complications even after controlling for patient characteristics, and an increased rate of secondary tuberculosis among dependents.
interpretationIn the USA, the median health-care delay for privately insured patients with tuberculosis exceeds WHO-recommended levels of 21 days (3 weeks). The results suggest the need for health-care provider education on best practices in tuberculosis diagnosis, including the use of molecular tests and the maintenance of a high index of suspicion for the disease.
fundingUS National Institutes of Health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.